id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-N-0304-0051,FDA,FDA-2006-N-0304,"Use of Ozone-Depleting Substances: Removal of Essential-Use Designation (Flunisolide, etc.); Correction",Notice,NCR-Notice of Correction,2010-09-17T04:00:00Z,2010,9,2010-09-17T04:00:00Z,,2011-06-11T16:25:59Z,2010-23195,0,0,0900006480b51d24
FDA-2006-N-0304-0050,FDA,FDA-2006-N-0304,"OMB Changes, Executive Order 12866 (E.O.) [Use of Ozone-Depleting Substances; Removal of Essential-Use Designations (Flunisolide, etc.)] - Reference",Other,REF-Reference Material (internal attachments),2010-04-27T04:00:00Z,2010,4,2010-04-27T04:00:00Z,,2013-07-27T23:17:05Z,,0,0,0900006480ae1652
FDA-2006-N-0304-0045,FDA,FDA-2006-N-0304,"Reference 07  - U.S. Environmental Protection Agency. ""The Benefits and Costs of the Clean Air Act: 1990-2010"" [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:58Z,,0,0,0900006480ad651c
FDA-2006-N-0304-0040,FDA,FDA-2006-N-0304,List  of References - [FDA-2006-N-0304 Notice of Final Rule 4/14/2010],Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:50Z,,0,0,0900006480ad5ea8
FDA-2006-N-0304-0044,FDA,FDA-2006-N-0304,"Reference 06 - United Nations Environmental Programme, Production and Consumption of Ozone-Depleting Substances: 1986-2004, 2005. [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:56Z,,0,0,0900006480ad651b
FDA-2006-N-0304-0043,FDA,FDA-2006-N-0304,"Reference 04 - Envrios March, Study on the Use of HFCs for Metered Dose Inhalers In the European Union: Final report following submission to the ECCP (European Commission Climate Change Policy Group)  [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:55Z,,0,0,0900006480ad5eac
FDA-2006-N-0304-0042,FDA,FDA-2006-N-0304,"Reference 03 - US Department of Commerce, Census Bureau; Economics and Statistics Administration, Pharmaceutical Preparation Manufacturing: 2002 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:53Z,,0,0,0900006480ad5eab
FDA-2006-N-0304-0049,FDA,FDA-2006-N-0304,"Reference 15 -  DeNavas-Walt, C. B. D. Proctor, and J. C Smith, U.S. Census Bureau, Current Population Reports, P60-236(RV), Income, Poverty, and Health Insurance Coverage in the United States: 2008, Table 7, p. 21. 2009 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:51:03Z,,0,0,0900006480ad6348
FDA-2006-N-0304-0046,FDA,FDA-2006-N-0304,"Reference 08 - American Lung Association, ""Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality,"" [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:59Z,,0,0,0900006480ad651d
FDA-2006-N-0304-0039,FDA,FDA-2006-N-0304,"Use of Ozone-Depleting Substances; Removal of Essential-Use Designation: Flunisolide, etc.",Rule,NFR-Notice of Final Rule,2010-04-14T04:00:00Z,2010,4,2010-04-14T04:00:00Z,,2011-06-11T16:25:59Z,2010-08467,0,0,0900006480ad7218
FDA-2006-N-0304-0041,FDA,FDA-2006-N-0304,"Reference 01 - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3), NIH Publication No. 07-4051 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:50:52Z,,0,0,0900006480ad5ea9
FDA-2006-N-0304-0047,FDA,FDA-2006-N-0304,"Reference 09 - American Lung Association, ""Trends in Asthma Morbidity and Mortality,"" January 2009 [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:51:01Z,,0,0,0900006480ad651e
FDA-2006-N-0304-0048,FDA,FDA-2006-N-0304,"Reference 11 - Analysis completed by FDA based on information provided by IMS Health,  [FDA-2006-N-0304 Notice of Final Rule, 4/14/2010]",Supporting & Related Material,BKG-Background Material,2010-04-14T04:00:00Z,2010,4,,,2010-04-14T14:51:02Z,,0,0,0900006480ad6572
FDA-2006-N-0304-0038,FDA,FDA-2006-N-0304,"Graceway Pharmaceuticals, LLC - Supplement Comment re FDA-2006-N-0304-0032",Other,SUP-Supplement,2010-02-03T05:00:00Z,2010,2,2010-02-03T05:00:00Z,,2013-07-27T23:05:37Z,,0,0,0900006480a8731b